1.Research progress on natural cannabinoid receptor type 2( CB2R)regulators and their effects on bone metabolism.
Si-Jing HU ; Chen-Xia LIAN ; Tao YU ; Qi ZAHNG ; Quan-Long ZHANG ; Qiao-Yan ZHANG ; Lu-Ping QIN
China Journal of Chinese Materia Medica 2021;46(14):3540-3550
Cannabinoid receptor type 2( CB2 R),a member of the G protein-coupled receptor( GPCR) superfamily,has a variety of biological activities,such as regulating pain response,resisting inflammation and fibrosis,and mediating bone metabolism. Some CB2 R regulators exhibit a good regulatory effect on bone metabolism. Cannabinoids in Cannabis sativa can cause psychoactive effects despite various pharmacological actions they exerted by targeting CB2 R. Therefore,it is of great significance to discover CB2 R regulators in non-Cannabis plants for finding new lead compounds without psychoactive effects and elucidating the action mechanism of plant drugs. The present study clarifies the discovery,structure,and physiological functions of CB2 R,especially its regulatory effects on bone metabolism,summarized CB2 R regulators extracted from non-Cannabis plants,and systematically analyzes the regulatory effects of CB2 R regulators on bone metabolism in animals,osteoblasts,and osteoclasts,to provide a scientific basis for the discovery of new CB2 R regulators and the development of anti-osteoporotic drugs.
Animals
;
Cannabinoids/pharmacology*
;
Cannabis
;
Osteoblasts
;
Osteoclasts
;
Receptors, Cannabinoid
2.Research progress on anti-inflammatory effects of plant-derived cannabinoid type 2 receptor modulators.
Chen-Xia LIAN ; Si-Jing HU ; Qiao-Yan ZHANG ; Qi-Ming ZHAO ; Lu-Ping QIN ; Wan GONG
China Journal of Chinese Materia Medica 2023;48(23):6294-6306
Excessive and persistent inflammatory responses are a potential pathological condition that can lead to diseases of various systems, including nervous, respiratory, digestive, circulatory, and endocrine systems. Cannabinoid type 2 receptor(CB2R) belongs to the G protein-coupled receptor family and is widely distributed in immune cells, peripheral tissues, and the central nervous system. It plays a role in inflammatory responses under various pathological conditions. The down-regulation of CB2R activity is an important marker of inflammation and and CB2R modulators have been shown to have anti-inflammatory effects. This study explored the relationship between CB2R and inflammatory responses, delved into its regulatory mechanisms in inflammatory diseases, and summarized the research progress on CB2R modulators from plants other than cannabis, including plant extracts and monomeric compounds, in exerting anti-inflammatory effects. The aim is to provide new insights into the prevention and treatment of inflammatory diseases.
Cannabinoid Receptor Modulators/pharmacology*
;
Cannabinoid Receptor Agonists/pharmacology*
;
Receptors, Cannabinoid
;
Cannabinoids/pharmacology*
;
Anti-Inflammatory Agents/pharmacology*
3.Role of Cannabinoid CB1 Receptor in Object Recognition Memory Impairment in Chronically Rapid Eye Movement Sleep-deprived Rats.
Kaveh SHAHVEISI ; Seyedeh MARZIYEH HADI ; Hamed GHAZVINI ; Mehdi KHODAMORADI
Chinese Medical Sciences Journal 2023;38(1):29-37
Objective We aimed to investigate whether antagonism of the cannabinoid CB1 receptor (CB1R) could affect novel object recognition (NOR) memory in chronically rapid eye movement sleep-deprived (RSD) rats.Methods The animals were examined for recognition memory following a 7-day chronic partial RSD paradigm using the multiple platform technique. The CB1R antagonist rimonabant (1 or 3 mg/kg, i.p.) was administered either at one hour prior to the sample phase for acquisition, or immediately after the sample phase for consolidation, or at one hour before the test phase for retrieval of NOR memory. For the reconsolidation task, rimonabant was administered immediately after the second sample phase.Results The RSD episode impaired acquisition, consolidation, and retrieval, but it did not affect the reconsolidation of NOR memory. Rimonabant administration did not affect acquisition, consolidation, and reconsolidation; however, it attenuated impairment of the retrieval of NOR memory induced by chronic RSD.Conclusions These findings, along with our previous report, would seem to suggest that RSD may affect different phases of recognition memory based on its duration. Importantly, it seems that the CB1R may, at least in part, be involved in the adverse effects of chronic RSD on the retrieval, but not in the acquisition, consolidation, and reconsolidation, of NOR memory.
Rats
;
Animals
;
Rimonabant/pharmacology*
;
Memory
;
Sleep, REM
;
Receptors, Cannabinoid
;
Cannabinoids/pharmacology*
4.Cannabinoids inhibit ATP-activated currents in rat trigeminal ganglionic neurons.
Jing-Jing SHEN ; Chang-Jin LIU ; Ai LI ; Xin-Wu HU ; Yong-Li LU ; Lei CHEN ; Ying ZHOU ; Lie-Ju LIU
Acta Physiologica Sinica 2007;59(6):745-752
The present study aimed to investigate whether cannabinoids could modulate the response mediated by ATP receptor (P2X purinoceptor). Whole-cell patch-clamp recording was performed on cultured rat trigeminal ganglionic (TG) neurons. The majority of TG neurons were sensitive to ATP (67/75, 89.33%). Extracellular pretreatment with WIN55212-2, a cannabinoid receptor 1 (CB1 receptor) agonist, reduced ATP-activated current (I(ATP)) significantly. This inhibitory effect was concentration-dependent and was blocked by AM281, a specific CB1 receptor antagonist. Pretreatment with WIN55212-2 at 1×10(-13), 1×10(-12), 1×10(-11), 1×10(-10), 1×10(-9) and 1×10(-8) mol/L reduced I(ATP) (induced by 1×10(-4) mol/L ATP) by (8.14±3.14)%, (20.11±2.72)%, (46.62±3.51)%, (72.16±5.64)%, (80.21±2.80)% and (80.59±3.55)%, respectively. The concentration-response curves for I(ATP) pretreated with and without WIN55212-2 showed that WIN55212-2 shifted the curve downward, and decreased the maximal amplitude of I(ATP) by (58.02±4.21)%. But the threshold value and EC(50) (1.15×10(-4) mol/L vs 1.27×10(-4) mol/L) remained unchanged. The inhibition of I(ATP) by WIN55212-2 was reversed by AM281, suggesting that the inhibition was mediated via the CB1 receptor. Pretreatment with forskolin [an agonist of adenylyl cyclase (AC)] or 8-Br-cAMP reversed the inhibition of I(ATP) by WIN55212-2. These results suggest that the inhibitory effect of cannabinoids on I(ATP) is mediated via the CB1 receptors, that lead to inhibition of the AC-cAMP-PKA signaling pathway.
Adenosine Triphosphate
;
physiology
;
Animals
;
Benzoxazines
;
pharmacology
;
Cannabinoids
;
pharmacology
;
Morpholines
;
pharmacology
;
Naphthalenes
;
pharmacology
;
Neurons
;
drug effects
;
physiology
;
Patch-Clamp Techniques
;
Pyrazoles
;
pharmacology
;
Rats
;
Receptor, Cannabinoid, CB1
;
agonists
;
antagonists & inhibitors
;
Signal Transduction
;
Trigeminal Ganglion
;
drug effects
;
physiology
5.Pharmacological intervention of conditioned fear and its extinction.
Renzhi HUANG ; Zexuan LI ; Huan CHEN ; Yuesheng HUANG ; Liping DING
Journal of Central South University(Medical Sciences) 2012;37(9):968-972
Conditioned fear and its abnormal extinction are involved in the psychopathology of anxiety disorders, such as posttraumatic stress disorder (PTSD). Cognitive enhancing agents have been demonstrated to alter fear extinction in many animal research literatures. The present review has examined the pharmacological role of gamma-aminobutyric acid (GABA), glutamatergic, cholinergic, adrenergic, dopaminergic, and cannabinoid as well as compounds able to alter the epigenetic and neurotrophic mechanism in fear extinction, highlighting great hope for the future treatment of anxiety disorders with new agents based on the fear extinction.
Animals
;
Anxiety Disorders
;
drug therapy
;
psychology
;
Cannabinoids
;
pharmacology
;
therapeutic use
;
Conditioning, Psychological
;
drug effects
;
Extinction, Psychological
;
drug effects
;
Fear
;
drug effects
;
psychology
;
Humans
;
Nootropic Agents
;
pharmacology
;
Stress Disorders, Post-Traumatic
;
drug therapy
;
psychology
;
gamma-Aminobutyric Acid
;
pharmacology
;
therapeutic use
6.Protective effect of intervention with cannabinoid type-2 receptor agonist JWH133 on pulmonary fibrosis in mice.
Xiao WU ; Wen Ting YANG ; Yi Ju CHENG ; Lin PAN ; Yu Quan ZHANG ; Hong Lan ZHU ; Meng Lin ZHANG
Chinese Journal of Internal Medicine 2023;62(7):841-849
Objective: JWH133, a cannabinoid type 2 receptor agonist, was tested for its ability to protect mice from bleomycin-induced pulmonary fibrosis. Methods: By using a random number generator, 24 C57BL/6J male mice were randomly divided into the control group, model group, JWH133 intervention group, and JWH133+a cannabinoid type-2 receptor antagonist (AM630) inhibitor group, with 6 mice in each group. A mouse pulmonary fibrosis model was established by tracheal instillation of bleomycin (5 mg/kg). Starting from the first day after modeling, the control group mice were intraperitoneally injected with 0.1 ml of 0.9% sodium chloride solution, and the model group mice were intraperitoneally injected with 0.1 ml of 0.9% sodium chloride solution. The JWH133 intervention group mice were intraperitoneally injected with 0.1 ml of JWH133 (2.5 mg/kg, dissolved in physiological saline), and the JWH133+AM630 antagonistic group mice were intraperitoneally injected with 0.1 ml of JWH133 (2.5 mg/kg) and AM630 (2.5 mg/kg). After 28 days, all mice were killed; the lung tissue was obtained, pathological changes were observed, and alveolar inflammation scores and Ashcroft scores were calculated. The content of type Ⅰ collagen in the lung tissue of the four groups of mice was measured using immunohistochemistry. The levels of interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) in the serum of the four groups of mice were measured using enzyme-linked immunosorbent assay (ELISA), and the content of hydroxyproline (HYP) in the lung tissue of the four groups of mice was measured. Western blotting was used to measure the protein expression levels of type Ⅲ collagen, α-smooth muscle actin (α-SMA), extracellular signal regulated kinase (ERK1/2), phosphorylated P-ERK1/2 (P-ERK1/2), and phosphorylated ribosome S6 kinase type 1 (P-p90RSK) in the lung tissue of mice in the four groups. Real-time quantitative polymerase chain reaction was used to measure the expression levels of collagen Ⅰ, collagen Ⅲ, and α-SMA mRNA in the lung tissue of the four groups of mice. Results: Compared with the control group, the pathological changes in the lung tissue of the model group mice worsened, with an increase in alveolar inflammation score (3.833±0.408 vs. 0.833±0.408, P<0.05), an increase in Ashcroft score (7.333±0.516 vs. 2.000±0.633, P<0.05), an increase in type Ⅰ collagen absorbance value (0.065±0.008 vs. 0.018±0.006, P<0.05), an increase in inflammatory cell infiltration, and an increase in hydroxyproline levels [(1.551±0.051) μg/mg vs. (0.974±0.060) μg/mg, P<0.05]. Compared with the model group, the JWH133 intervention group showed reduced pathological changes in lung tissue, decreased alveolar inflammation score (1.833±0.408, P<0.05), decreased Ashcroft score (4.167±0.753, P<0.05), decreased type Ⅰ collagen absorbance value (0.032±0.004, P<0.05), reduced inflammatory cell infiltration, and decreased hydroxyproline levels [(1.148±0.055) μg/mg, P<0.05]. Compared with the JWH133 intervention group, the JWH133+AM630 antagonistic group showed more severe pathological changes in the lung tissue of mice, increased alveolar inflammation score and Ashcroft score, increased type Ⅰ collagen absorbance value, increased inflammatory cell infiltration, and increased hydroxyproline levels. Compared with the control group, the expression of α-SMA, type Ⅲ collagen, P-ERK1/2, and P-p90RSK proteins in the lung tissue of the model group mice increased, while the expression of type Ⅰ collagen, type Ⅲ collagen, and α-SMA mRNA increased. Compared with the model group, the protein expression of α-SMA (relative expression 0.60±0.17 vs. 1.34±0.19, P<0.05), type Ⅲ collagen (relative expression 0.52±0.09 vs. 1.35±0.14, P<0.05), P-ERK1/2 (relative expression 0.32±0.11 vs. 1.14±0.14, P<0.05), and P-p90RSK (relative expression 0.43±0.14 vs. 1.15±0.07, P<0.05) decreased in the JWH133 intervention group. The type Ⅰ collagen mRNA (2.190±0.362 vs. 5.078±0.792, P<0.05), type Ⅲ collagen mRNA (1.750±0.290 vs. 4.935±0.456, P<0.05), and α-SMA mRNA (1.588±0.060 vs. 5.192±0.506, P<0.05) decreased. Compared with the JWH133 intervention group, the JWH133+AM630 antagonistic group increased the expression of α-SMA, type Ⅲ collagen, P-ERK1/2, and P-p90RSK protein in the lung tissue of mice, and increased the expression of type Ⅲ collagen and α-SMA mRNA. Conclusion: In mice with bleomycin-induced pulmonary fibrosis, the cannabinoid type-2 receptor agonist JWH133 inhibited inflammation and improved extracellular matrix deposition, which alleviated lung fibrosis. The underlying mechanism of action may be related to the activation of the ERK1/2-RSK1 signaling pathway.
Mice
;
Male
;
Animals
;
Pulmonary Fibrosis/pathology*
;
Cannabinoid Receptor Agonists/metabolism*
;
Collagen Type I/pharmacology*
;
Collagen Type III/pharmacology*
;
Hydroxyproline/pharmacology*
;
Sodium Chloride/metabolism*
;
Mice, Inbred C57BL
;
Lung/pathology*
;
Cannabinoids/adverse effects*
;
Bleomycin/metabolism*
;
Collagen/metabolism*
;
Inflammation/pathology*
;
RNA, Messenger/metabolism*
7.SR144528 as Inverse Agonist of CB2 Cannabinoid Receptor.
Journal of Veterinary Science 2002;3(3):179-184
It is now well established that several G protein- coupled receptors can signal without agonist stimulation (constitutive receptors). Inverse agonists have been shown to inhibit the activity of such constitutive G protein-coupled receptor signaling. Agonist activation of the Gi/o-coupled peripheral cannabinoid receptor CB2 normally inhibits adenylyl cyclase type V and stimulates adenylyl cyclase type II. Using transfected COS cells, we show here that application of SR144528, an inverse agonist of CB2, leads to a reverse action (stimulation of adenylyl cyclase V and inhibition of adenylyl cyclase II). This inverse agonism of SR144528 is dependent on the temperature, as well as on the concentration of the cDNA of CB2 transfected. Pertussis toxin blocked the regulation of adenylyl cyclase activity by SR 144528.
Adenylate Cyclase/antagonists&inhibitors/genetics/metabolism
;
Animals
;
Binding, Competitive
;
Bornanes/metabolism/*pharmacology
;
COS Cells
;
Cannabinoids/metabolism
;
Cercopithecus aethiops
;
Isoenzymes/antagonists&inhibitors/genetics/metabolism
;
Pyrazoles/metabolism/*pharmacology
;
Rats
;
*Receptor, Cannabinoid, CB2
;
Receptors, Cannabinoid
;
Receptors, Drug/agonists/*antagonists&inhibitors/genetics/metabolism
;
Signal Transduction/drug effects/physiology
;
Transfection
8.Research progress of role of cannabinoid receptor in fibrosis.
Shanshan LI ; Linlin WANG ; Min LIU ; Yanling GAO ; Zhiling TIAN ; Shukun JIANG ; Miao ZHANG ; Dawei GUAN
Chinese Journal of Pathology 2014;43(2):136-138
Animals
;
Cannabinoid Receptor Antagonists
;
therapeutic use
;
Cannabinoids
;
pharmacology
;
Fibrosis
;
metabolism
;
Humans
;
Liver Cirrhosis
;
etiology
;
metabolism
;
therapy
;
Piperidines
;
therapeutic use
;
Pyrazoles
;
therapeutic use
;
Receptor, Cannabinoid, CB1
;
metabolism
;
Receptor, Cannabinoid, CB2
;
metabolism
;
Receptors, Cannabinoid
;
metabolism
;
Scleroderma, Diffuse
;
metabolism
;
Signal Transduction
;
drug effects
;
Skin
;
metabolism
;
Smad Proteins
;
metabolism
;
Transforming Growth Factor beta1
;
metabolism